All Releases
 |
VIVUS to Present at the 9th Annual BIO Asia International Partnering Conference
Jan 26, 2012
|
59.5 KB |
|
| |
MOUNTAIN VIEW, Calif., Jan. 26, 2012 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced that the Company will present at the 9th Annual BIO Asia International Conference, January 31 — February 1, 2012, in Osaka, Japan. The VIVUS presentation will take place on Tuesday, January 31, 2012 at 1:30PM JST at The Ritz-Carlton, Osaka.
...
|
|
REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function
Jan 17, 2012
|
15.4 KB |
|
| |
MOUNTAIN VIEW, Calif., Jan. 17, 2012 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that results from the REVIVE study were published in The Journal of Sexual Medicine (JSM), a peer-reviewed journal with broad, multidisciplinary readership. REVIVE (TA-301) was a randomized, placebo-controlled, phase 3 study evaluating the safety and eff...
|
|
VIVUS Provides Qnexa Regulatory Update
Jan 9, 2012
|
61.3 KB |
|
| |
MOUNTAIN VIEW, Calif., Jan. 9, 2012 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that following recent discussions with Food and Drug Administration (FDA) officials, the company has been asked to remove the Qnexa® contraindication for women of childbearing potential contained in the proposed label. Qnexa would remain contraindic...
|
|
VIVUS to Present at the 2012 JP Morgan Healthcare Conference
Jan 4, 2012
|
13.3 KB |
|
| |
MOUNTAIN VIEW, Calif., Jan. 4, 2012 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that the Company will present at the 30th Annual JP Morgan Healthcare Conference.
The VIVUS presentation will take place at the Westin St. Francis Hotel in San Francisco, CA on Monday, January 9, 2012 at 9:00 a.m. PT. A live webcast and 30-day arc...
|
|
VIVUS Announces Date of FDA Advisory Committee Review of Qnexa for the Treatment of Obesity
Dec 23, 2011
|
14.0 KB |
|
| |
MOUNTAIN VIEW, Calif., Dec. 23, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is scheduled to review the Company's New Drug Application (NDA) for Qnexa for the treatment of obesity on February 22, 2012. VIVUS resubmitted t...
|
|
VIVUS Reports Topline Findings From FORTRESS
Dec 21, 2011
|
15.7 KB |
|
| |
MOUNTAIN VIEW, Calif., Dec. 21, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced topline preliminary results from its retrospective study of medical claims data on oral clefts (OC) associated with topiramate exposure in utero. The study, known as FORTRESS for Fetal Outcome Retrospective TopiRamate ExpoSure Study, identified 1,945 mo...
|
|
SEQUEL Trial Results for Qnexa® Published in AJCN Show 10% Sustained Weight Loss Over 2 Years
Dec 8, 2011
|
17.7 KB |
|
| |
MOUNTAIN VIEW, Calif., Dec. 8, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that results from the SEQUEL study were published in The American Journal of Clinical Nutrition, a peer-reviewed journal with broad, multidisciplinary readership. The SEQUEL study evaluated the long-term efficacy and safety of Qnexa in 676 overweight and ...
|
|
Weight Loss and Effects on Diabetes with Qnexa Treatment Results Presented at the World Diabetes Congress
Dec 7, 2011
|
15.5 KB |
|
| |
MOUNTAIN VIEW, Calif., Dec. 7, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) announced that an oral presentation was given at the International Diabetes Federation's World Diabetes Congress, in Dubai, United Arab Emirates today. The presentation highlighted excess weight loss, improvement of glycemic parameters in diabetic patients with a BMI>35...
|
|
Avanafil Data Presented at the European Society of Sexual Medicine Meeting
Dec 5, 2011
|
61.8 KB |
|
| |
MOUNTAIN VIEW, Calif., Dec. 5, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts were presented over the weekend at the 2011 European Society of Sexual Medicine (ESSM) Meeting in Milan, Italy. The ESSM is the largest gathering of medical professionals specializing in sexual dysfunction and treatment in Europe....
|
|
VIVUS to Present at the Deutsche Bank BioFEST Conference
Dec 1, 2011
|
11.0 KB |
|
| |
MOUNTAIN VIEW, Calif., Dec. 1, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the 2011 Deutsche Bank BioFEST Conference.
The VIVUS presentation will take place at the Four Seasons Hotel, Boston, MA on Tuesday, December 6, 2011 at 10:20 a...
|
|
15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
Nov 14, 2011
|
13.1 KB |
|
| |
MOUNTAIN VIEW, Calif., Nov. 14, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that new analyses from TA-314, a phase 3 long-term safety and efficacy study of the investigational drug avanafil for the treatment of erectile dysfunction (ED), was presented over the weekend at the 2011 Sexual Medicine Society of North America (SMSNA) ...
|
|
Avanafil Data to be Presented at the Sexual Medicine Society of North America Meeting
Nov 10, 2011
|
61.6 KB |
|
| |
MOUNTAIN VIEW, Calif., Nov. 10, 2011 /PRNewswire/ --
Highlights from Avanafil Development Program Include:
Early onset of action observed in placebo-controlled trialsComparative in-vitro selectivity of avanafil, sildenafil, vardenafil and tadalafilSafety and efficacy in post-prostatectomy populationVIVUS, Inc. (NASDAQ: VVUS) today announced t...
|
|
VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results
Nov 7, 2011
|
25.5 KB |
|
| |
MOUNTAIN VIEW, Calif., Nov. 7, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today reported its financial results for the third quarter and nine months ended September 30, 2011.
Third Quarter Results
For the third quarter ended Se...
|
|
Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment
Nov 3, 2011
|
17.4 KB |
|
| |
MOUNTAIN VIEW, Calif., Nov. 3, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that results from the 56-week EQUIP study were published in Obesity, the peer-reviewed journal of The Obesity Society. The EQUIP study evaluated the efficacy and safety of the investigational drug Qnexa in 1,267 severely obese (BMI >/= 35 kg/m2) patients ...
|
|
FDA Accepts New Drug Application Filing for Qnexa
Nov 3, 2011
|
61.2 KB |
|
| |
MOUNTAIN VIEW, Calif., Nov. 3, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the New Drug Application (NDA) for Qnexa® to treat obesity. The company resubmitted the NDA on October 17, 2011.
The agency assigned a six-month, or class 2, revie...
|
|
VIVUS to Present at the Credit Suisse 2011 Healthcare Conference
Nov 3, 2011
|
9.1 KB |
|
| |
MOUNTAIN VIEW, Calif., Nov. 3, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the Credit Suisse 2011 Healthcare Conference.
The VIVUS presentation will take place at the Arizona Biltmore Hotel in Phoenix, AZ on Thursday, November 10, 201...
|
|
VIVUS Announces Date of Third Quarter 2011 Financial Results and Conference Call
Oct 28, 2011
|
9.5 KB |
|
| |
MOUNTAIN VIEW, Calif., Oct. 28, 2011 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced that it will report financial results for the third quarter ended September 30, 2011 after the NASDAQ Market closes on Monday, November 7, 2011.
Date:
November 7, 2011
Time:
...
|
|
VIVUS Resubmits Qnexa NDA to the FDA
Oct 17, 2011
|
12.2 KB |
|
| |
MOUNTAIN VIEW, Calif., Oct. 17, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that the company has resubmitted the New Drug Application (NDA) for Qnexa® to the U.S. Food and Drug Administration (FDA). The resubmission follows an agreement reached in September 2011 with officials of the Endocrine and Metabolic Division of the ...
|
|
VIVUS to Present at the BioCentury NewsMakers Conference
Oct 14, 2011
|
8.9 KB |
|
| |
MOUNTAIN VIEW, Calif., Oct. 14, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the 2011 BioCentury NewsMakers in the Biotech Industry Conference.
The VIVUS presentation will take place at the Millennium Broadway Hotel in New York, NY on Frid...
|
|
Two-year Treatment With Qnexa Has Benefits Beyond Weight Loss
Oct 3, 2011
|
15.9 KB |
|
| |
MOUNTAIN VIEW, Calif., Oct. 3, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts were presented at Obesity 2011: The 29th Annual Scientific Meeting of The Obesity Society being held in Orlando, Florida. The presentations highlighted the long-term beneficial effects of Qnexa® treatment in addition to doubl...
|
|
|
= add release to Briefcase |
Shareholder Briefcase
Email Alerts
Download Library
RSS News Feeds